Fda black sits at the center of this dementia and brain health question.
In September 2025, the FDA initiated a significant label change for acetaminophen — the active ingredient in Tylenol and the single most widely used over-the-counter pain reliever and fever reducer in the United States — to warn that use during pregnancy may be associated with an increased risk of autism and ADHD in children. While this was technically a label change rather than a formal black box warning, it represents one of the most consequential FDA safety actions of the past year, affecting a drug that roughly 65 percent of pregnant women in the U.S. have reported using at some point during pregnancy. For families navigating dementia care and brain health, this development raises broader questions about how common medications interact with neurodevelopmental outcomes across the lifespan.
But acetaminophen was not the only drug to receive heightened FDA scrutiny. In the same period, the agency added formal boxed warnings to Elevidys, a gene therapy for Duchenne muscular dystrophy, after two pediatric deaths from acute liver failure, and to CARVYKTI, a CAR-T cancer therapy linked to a dangerous new form of gut inflammation. Meanwhile, the FDA took the unusual step of removing warnings from two drug classes — pulling suicidal ideation warnings from GLP-1 medications like Wegovy and Zepbound in January 2026, and initiating the removal of long-standing black box warnings from hormone replacement therapy drugs. This article walks through each of these actions, what they mean for patients and caregivers, and why they matter for anyone concerned with brain health.
Table of Contents
- What Exactly Did the FDA Change About Acetaminophen, and Why Now?
- How Boxed Warnings Differ From Label Changes and Why the Distinction Matters
- Elevidys and CARVYKTI — When Breakthrough Therapies Carry Lethal Risks
- GLP-1 Medications Cleared of Suicide Risk — What Caregivers Should Know
- Hormone Replacement Therapy Warnings Rolled Back After Decades of Debate
- What This Means for People Managing Multiple Medications
- The Bigger Picture — How the FDA’s Approach to Drug Safety Is Evolving
- Conclusion
- Frequently Asked Questions
What Exactly Did the FDA Change About Acetaminophen, and Why Now?
On September 22, 2025, the fda responded to a growing body of epidemiological evidence suggesting that acetaminophen use during pregnancy may be linked to neurodevelopmental conditions in children, specifically autism spectrum disorder and attention-deficit/hyperactivity disorder. Multiple large-scale studies, including the Nurses’ Health Study II and the Boston Birth Cohort, found that the association was strongest when acetaminophen was taken for four or more consecutive weeks during pregnancy. The FDA determined that this evidence warranted updated labeling so that pregnant women and their healthcare providers could make more informed decisions. The critical caveat here is that a causal relationship has not been established. The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics still consider acetaminophen safe during pregnancy. The studies that triggered the label change are observational, meaning they show correlation but cannot rule out confounding factors — for example, the underlying condition causing the pain or fever may itself contribute to neurodevelopmental risk.
This is not a recall or a ban. It is the FDA saying: here is what the evidence shows, and you deserve to know about it. What makes this situation particularly difficult is that acetaminophen remains the only over-the-counter drug approved for treating fevers during pregnancy. Aspirin carries risks of bleeding complications, and ibuprofen and other NSAIDs have well-documented fetal risks including premature closure of the ductus arteriosus. So for a pregnant woman running a high fever — which itself poses risks to fetal development — acetaminophen is still the recommended option. The label change is not meant to scare women away from the drug entirely but to encourage conversations with doctors about duration of use and whether alternatives or non-pharmacological approaches might work in certain situations.
How Boxed Warnings Differ From Label Changes and Why the Distinction Matters
The FDA’s black box warning, formally known as a “boxed warning,” is the agency’s most serious safety alert. It appears as a bold, black-bordered section at the top of a drug’s prescribing information and signals risks severe enough that they could lead to death or permanent disability. Not every safety action the FDA takes qualifies as a boxed warning, and understanding the hierarchy matters when you are evaluating your own medications or those of someone you care for. The acetaminophen action, for instance, was a label change — significant, but a step below the boxed warning level. By contrast, the warnings added to Elevidys and CARVYKTI in late 2025 were full boxed warnings, triggered by fatal outcomes directly linked to the therapies. The distinction matters practically: a boxed warning often comes with new prescribing restrictions, mandatory monitoring requirements, or limits on which patients can receive the drug.
A label change updates the information available to patients and clinicians but typically does not restrict access. However, if you are a caregiver managing medications for someone with dementia or other cognitive conditions, even a label change should prompt a conversation with their physician, because the risks and benefits of any drug shift as a person’s health status changes. One limitation to keep in mind is that FDA safety actions are often reactive rather than preventive. The agency relies on post-market surveillance, adverse event reports, and published research to identify problems that may not have been apparent in clinical trials. This means that a drug can be on the market for years — or in acetaminophen’s case, decades — before a new risk signal emerges. For caregivers, the practical takeaway is to stay current with FDA announcements for any medication that is part of a daily routine, particularly for older adults who may be on multiple drugs simultaneously.
Elevidys and CARVYKTI — When Breakthrough Therapies Carry Lethal Risks
On November 14, 2025, the FDA added a boxed warning to Elevidys, a gene therapy manufactured by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy. The warning was triggered by two pediatric deaths from acute liver failure in non-ambulatory patients, both of whom developed elevated liver enzymes and required hospitalization within two months of receiving the infusion. In response, the FDA restricted the indication to ambulatory patients aged four and older and imposed new monitoring requirements: weekly liver function tests for at least three months after treatment, and a requirement that patients remain near a medical facility for at least two months post-infusion. Sarepta had already voluntarily suspended distribution to non-ambulatory patients in June 2025, months before the formal FDA action. The CARVYKTI case followed a similar pattern.
On October 10, 2025, the FDA added a boxed warning to this CAR-T cell therapy, manufactured by Johnson & Johnson and Legend Biotech, for a newly identified condition called immune effector cell-associated enterocolitis. Patients experienced severe and prolonged diarrhea, abdominal pain, and significant weight loss in the weeks and months following treatment. Fatal outcomes occurred from gut perforation and sepsis. Despite these risks, the FDA determined that the overall benefit of CARVYKTI — including a demonstrated overall survival advantage in certain blood cancers — still outweighed the dangers, so the drug remains available with enhanced warnings. These cases may seem far removed from dementia care, but they illustrate a principle that applies across medicine: the most innovative therapies often carry the most unpredictable risks. As experimental treatments for Alzheimer’s disease and other neurodegenerative conditions reach the market — some of which, like the amyloid-targeting antibodies, already carry their own serious side effects — the Elevidys and CARVYKTI precedents offer a preview of how the FDA balances access to potentially life-changing treatments against the reality of fatal complications in a subset of patients.
GLP-1 Medications Cleared of Suicide Risk — What Caregivers Should Know
In one of the more reassuring FDA actions of the past year, the agency requested on January 13, 2026, the removal of suicidal ideation and behavior warnings from GLP-1 receptor agonist medications, a class that includes Wegovy and Ozempic (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide). These drugs, originally developed for type 2 diabetes and now widely prescribed for weight management, had carried the warning based on early safety signals. After a thorough review that controlled for baseline confounders — including pre-existing mental health conditions — the FDA found no increased risk of intentional self-harm in GLP-1 users compared to users of SGLT2 inhibitors, another class of diabetes medication. This matters for the dementia care community for a specific reason: emerging research has explored GLP-1 drugs as potential neuroprotective agents, with some studies suggesting they may reduce neuroinflammation and improve insulin signaling in the brain. The removal of the suicide warning removes one barrier — psychological if not regulatory — to considering these medications for older adults who might benefit from them, particularly those with overlapping metabolic and cognitive risk factors.
However, the long-term neurological effects of GLP-1 drugs remain under investigation, and no GLP-1 medication is currently approved for the treatment or prevention of dementia. Anyone considering these drugs for off-label cognitive purposes should do so only under close medical supervision. The tradeoff to weigh is that while the suicide risk appears to have been a false alarm, GLP-1 medications carry other well-established side effects including nausea, gastroparesis, and in rare cases pancreatitis. For older adults, particularly those who are already underweight or have difficulty maintaining nutrition — a common problem in mid-to-late stage dementia — the appetite-suppressing effects of these drugs could do more harm than good. The FDA clearing the suicide warning does not mean these drugs are risk-free; it means one specific concern has been addressed.
Hormone Replacement Therapy Warnings Rolled Back After Decades of Debate
In November 2025, the FDA initiated the removal of black box warnings from hormone replacement therapy drugs, a move that effectively reverses one of the most consequential and controversial safety decisions of the early 2000s. For more than two decades, HRT medications carried stark warnings based largely on the Women’s Health Initiative study, which linked estrogen-progestin therapy to increased risks of breast cancer, heart disease, stroke, and blood clots. Those findings led millions of women to abandon HRT, often enduring severe menopausal symptoms rather than accept the perceived dangers. The FDA’s reassessment acknowledges what many clinicians have argued for years: the risks and benefits of HRT depend heavily on a patient’s age and how close they are to the onset of menopause. For women who begin HRT within ten years of menopause or before age sixty, the benefits — including relief from hot flashes, protection against bone loss, and potentially reduced cardiovascular risk — often outweigh the dangers.
The blanket black box warning, the FDA now concedes, did not adequately capture this nuance and may have discouraged appropriate use in women who stood to benefit most. For families dealing with dementia, this is relevant because estrogen has long been studied for its potential neuroprotective effects. Some research suggests that estrogen therapy initiated during the critical perimenopausal window may reduce the risk of Alzheimer’s disease, while therapy initiated later in life may actually increase risk. The removal of the black box warning does not settle this debate, but it does open the door for more individualized conversations between women and their doctors about whether HRT might serve both their menopausal and long-term cognitive health. The limitation here is significant: no one should start HRT primarily to prevent dementia, because the evidence is not strong enough to support that as a standalone indication.
What This Means for People Managing Multiple Medications
For older adults and their caregivers, the cumulative effect of these FDA actions is a reminder that medication management is not a set-it-and-forget-it task. Consider a common scenario: an older woman taking acetaminophen for chronic arthritis pain, a GLP-1 medication for type 2 diabetes, and estrogen therapy for postmenopausal symptoms. In the span of a single year, the safety profile of every one of those drugs shifted in the eyes of the FDA.
None of those changes necessarily require an immediate change in her regimen, but all of them warrant a conversation with her prescribing physician at the next appointment. This is especially important for individuals with cognitive impairment, who may not be able to advocate for themselves in these conversations. Caregivers should maintain a current medication list, flag any FDA safety updates that apply, and bring them to every medical appointment. Pharmacists are also an underused resource — they can review the full medication list for interactions and flag drugs that have received recent FDA safety actions.
The Bigger Picture — How the FDA’s Approach to Drug Safety Is Evolving
What stands out about the 2025-2026 period is not just the individual drug actions but the FDA’s evolving willingness to both add and remove warnings based on updated evidence. The removal of the GLP-1 suicide warning and the rollback of HRT black box warnings signal an agency that is becoming more responsive to real-world data, rather than treating initial safety signals as permanent verdicts. This is a meaningful shift, because overly cautious warnings can be just as harmful as insufficient ones — they drive patients away from beneficial treatments and erode trust in regulatory guidance.
For those of us watching the Alzheimer’s drug pipeline, this evolution matters. Treatments like lecanemab and donanemab have entered the market with significant safety concerns, including brain swelling and microbleeds. How the FDA monitors, communicates, and — if the data warrant it — adjusts warnings for these drugs will shape whether patients and caregivers trust them enough to use them. The precedent set by the agency’s handling of GLP-1 and HRT warnings gives cautious reason for optimism that future safety actions will be grounded in evidence rather than reflexive caution.
Conclusion
The FDA’s safety actions over the past year tell a complex story. Acetaminophen, the most common drug in American medicine cabinets, now carries new pregnancy-related labeling that flags a possible association with autism and ADHD in children. Breakthrough therapies like Elevidys and CARVYKTI received the agency’s most serious warnings after fatal outcomes. And in a reversal that surprised many, warnings were lifted from GLP-1 medications and hormone replacement therapy as better data emerged.
Each of these decisions reflects a regulatory system grappling with incomplete evidence while trying to protect public health. For caregivers and anyone invested in brain health, the practical message is straightforward: stay informed, talk to your doctors, and do not assume that the safety label on any medication is permanent. The FDA’s actions this year demonstrate that drug safety is a living process, not a fixed conclusion. Whether you are managing your own medications or overseeing care for a loved one with dementia, the single most important thing you can do is keep the conversation with your healthcare team current — because the evidence certainly is not standing still.
Frequently Asked Questions
Is Tylenol still safe to take during pregnancy?
Acetaminophen remains the only FDA-approved OTC option for fever reduction during pregnancy, and both ACOG and the AAP still consider it acceptable for short-term use. The September 2025 label change highlights a possible association with autism and ADHD when used for four or more weeks, but no causal link has been established. The guidance is to use the lowest effective dose for the shortest duration necessary, and to discuss alternatives with your doctor for chronic pain.
What is the difference between a black box warning and a label change?
A black box warning, or boxed warning, is the FDA’s most serious safety alert and appears in a bold-bordered section at the top of prescribing information. It typically signals risks of death or serious harm and often comes with new prescribing restrictions. A label change updates safety information without imposing the same level of restriction. The acetaminophen pregnancy action was a label change; the Elevidys and CARVYKTI actions were full boxed warnings.
Should I stop taking a GLP-1 medication like Wegovy or Zepbound because of previous suicide warnings?
No. In January 2026, the FDA formally requested the removal of suicidal ideation and behavior warnings from GLP-1 medications after a comprehensive review found no increased risk compared to other diabetes drugs. If you have concerns about mood changes while on these medications, discuss them with your prescribing physician, but the data do not support a link between GLP-1 drugs and suicidal behavior.
Does hormone replacement therapy protect against dementia?
The evidence is mixed and depends heavily on timing. Some studies suggest that estrogen therapy initiated close to menopause onset may have neuroprotective effects, while therapy started later in life may increase cognitive risk. The FDA’s removal of the HRT black box warning does not constitute an endorsement of HRT for dementia prevention. It should not be started solely for that purpose based on current evidence.
Are FDA black box warnings permanent?
No. As demonstrated by the GLP-1 and HRT actions in late 2025 and early 2026, the FDA can and does remove or modify warnings when new evidence warrants it. Safety labeling is an ongoing process that reflects the best available data at any given time.
How can caregivers stay informed about FDA safety changes for medications their loved ones take?
Subscribe to FDA MedWatch alerts, which provide email notifications about safety updates for specific drugs. Maintain a current medication list and review it with a pharmacist or physician at least every six months. For individuals with cognitive impairment who cannot track these changes themselves, caregiver vigilance is the most reliable safeguard.
You Might Also Like
- Drug Recalled After FDA Discovers Contamination — Full List Inside
- FDA Approves First Drug for This Disease in 20 Years
- The Injectable Migraine Drug Working in 30 Minutes Flat
For more, see Alzheimer’s Association — medical tests.
